Novel approaches in oncology at AstraZeneca (Q59305043)

1

0 references

Trevor Stephens

2

0 references

Kate Byth

3

0 references

Tim Green

4

0 references

Steve Wedge

5

0 references

David Blakey

Tumor angiogenesis: therapeutic implications

6

0 references

publication date

October 2003

0 references

published in

EJC supplements

0 references

volume

1

0 references

issue

8

0 references

page(s)

3-8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Mechanisms of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Molecular regulation of vessel maturation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Role of Src expression and activation in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

SRC transcriptional activation in a subset of human colon cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Inhibiting Ras signaling in the therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021

Complexities in the development of cyclin-dependent kinase inhibitor drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2980014-9

7 January 2021